Sign in
Active, not recruitingPhase 3

MHB018A Treatment in Patients With Chronic Thyroid Eye Disease

Key facts

Who runs it
Minghui Pharmaceutical (Hangzhou) Ltd
Where
China1 site in 1 countryChoose a country to see its sites
Trial code
Status
Active, not recruiting
Phase
Phase 3
People taking part
150 people, planned
Started
17 Mar 2026
Expected to end
31 Aug 2028
Type of study
Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
Treatments tested
  • MHB018A injection
  • MHB018A injection Placebo
Record updated
24 September 2026

Who can take part

Age
18 years to 75 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 32 criteriaShow less

Who can take part

  • Subjects voluntarily participating in the study and signing the informed consent form
  • Aged 18-75 years (inclusive), of any gender
  • Clinical diagnosis of chronic Thyroid Eye Disease (TED) , with symptoms in the study eye more than 12 months and less than 10 years
  • Subjects with a clinical diagnosis of moderate to severe TED at screening and baseline
  • Does not require immediate surgical ophthalmological intervention, and no corrective surgery/orbital radiotherapy is planned during the study
  • Diabetic subjects must have well-controlled stable disease
  • Sufficient bone marrow and organ function
  • Eligible subjects of childbearing potential (male and female) must agree to use reliable contraceptive methods; female subjects of childbearing potential must have a negative blood pregnancy test within 7 days before the first use of the study drug and must not be breastfeeding
  • Subject is willing and able to comply with the prescribed treatment protocol and evaluations for the duration of the study; -

Who cannot take part

  • Subjects who have previously received orbital radiotherapy or ophthalmic surgery for TED
  • Subjects who received oral or intravenous corticosteroids or corticosteroid eye drops/ointments for TED within 4 weeks before the first dose; subjects who received periorbital/orbital steroid injections within 3 months before the first dose
  • Subjects who used oral or intravenous corticosteroids for reasons other than TED within 4 weeks prior to Screening, excluding local use (topical, nasal, inhalation)
  • Any previous treatment with rituximab, tocilizumab, other immunosuppressive agent use within 3 months prior to Screening
  • Previous treatment targeting IGF-1R
  • Selenium and biotin must be discontinued 3 weeks prior to Screening and must not be restarted during the trial; however, taking a multivitamin that includes selenium and/or biotin is allowed
  • Use of an investigational agent for any condition within 30 days prior to Screening or anticipated use during the course of the trial
  • Acute cardiovascular disease history or treatment within 6 months before the first dose
  • Drug or alcohol abuse during the screening period
  • Subjects who received or planned to receive live or attenuated live vaccines within 4 weeks before the first dose or during the study period
  • Subjects who underwent major surgery within 4 weeks before the first dose or are expected to undergo surgery during the study period or within 4 weeks after the study
  • Known hypersensitivity to any of the components of MNB018A or prior hypersensitivity reactions to mAbs; -
  • Identified pre-existing ophthalmic disease that, in the judgment of the Investigator, would preclude study participation or complicate interpretation of study results
  • Malignant condition in the past 5 years before signing the ICF (except successfully treated basal/squamous cell carcinoma of the skin)
  • Presence of poorly controlled hypertension with systolic blood pressure ≥ 160 mmHg or diastolic blood pressure ≥ 100 mmHg; Renal artery stenosis
  • Hearing impairment history in either ear during the screening period; or abnormal pure tone audiometry results
  • Biopsy-proven or clinically suspected inflammatory bowel disease
  • Positive results for serum virology tests (defined as pos
  • Decreased best corrected visual acuity due to optic neuropathy as defined by a decrease in vision within the last 6 months of two lines of Snellen chart, new visual field defect or color defect secondary to optic nerve involvement
  • Corneal decompensation unresponsive to medical management
  • Decrease in CAS of ≥ 2 points or decrease in proptosis of ≥ 2 mm between screening and baseline
  • Free thyroxine (FT4) and free triiodothyronine (FT3) levels <50% above or below the normal reference range at screening
  • Pregnant or lactating women

This trial has no sites in United States.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

The primary objective of this study is to investigate the efficacy, safety, and tolerability of MHB018A, a humanized anti-IGF1R antibody, administered Q4W for 6 months, in comparison to placebo, in the treatment of participants suffering from chronic TED.

The 2 groups in the trial

  • MHB018A InjectionTreatment being tested

    subcutaneous injections of MHB018A injection, 450mg once every 4 weeks (q4w).

  • MHB018A Injection PlaceboPlacebo, for comparison

    subcutaneous injections of MHB018A placebo once every 4 weeks (q4w)

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
A Phase III, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy of MHB018A Injection in Subjects With Chronic Moderate-to-Severe Thyroid Eye Disease.
Record updated
24 September 2026